World Health Organization Sounds Alert Over Acute Scarcity of Obesity Injections
Fewer than one in 10 patients who could benefit from weight-loss injections such as Wegovy can access them, warns the WHO as it releases its inaugural advice on the medications.
Considering in excess of 1,000,000,000 individuals worldwide currently classified as obese, it is urging increased and just availability to this class of drugs.
Per estimates, more than two billion could be living with obesity by 2030 without intervention.
"The latest guidelines affirms that obesity is a long-term condition that can be managed with holistic and continuous treatment," stated the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, limited production capacity, and logistical bottlenecks are key hurdles to broad access to the treatments that can help people shift substantial body mass, notes the agency.
Skinny Jab Supply Crisis
Even in the present best projected scenario, the production of these medications would only suffice for approximately 100 million people – less than 10% of those who need them, per the health organization.
The guideline encourages governments and firms to expand availability, via measures like voluntary licensing.
A patent on semaglutide – the main ingredient of the drug Wegovy – is scheduled to end in several countries in 2026.
The Way Obesity Jabs Operate
The injections mimick a body's own hormone to slow digestion, reduce hunger and enhance the sense of being full so users consume fewer calories.
People commonly see weight reduction in the initial weeks of beginning the once-weekly jabs.
Studies points to patients may regain a significant portion within a year of halting the treatment, when their typical appetite resume.
To be carrying excess weight increases your chance for experiencing medical conditions, including diabetes, cardiovascular issues, stroke, and specific cancers.
Obesity impacts individuals in every country and was responsible for 3.7 million fatalities worldwide in 2024, per the health agency.
